Author:
Ustun Mehmet,Sezer Taylan Ozgur
Publisher
Springer International Publishing
Reference33 articles.
1. Spratt JS, Adcock RA, Muscovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256–60.
2. Sugarbaker PH. It’s what the surgeon doesn’t see kills the patient. J Nippon Med Sch. 2000;67:5–8.
https://doi.org/10.1272/jnms.67.5
.
3. Elias D, Goere D, Dumont F, Honoré C, Dartigues P, Stoclin A, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer. 2014;50:332–40.
https://doi.org/10.1016/j.ejca.2013.09.024
.
4. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston, MA: Kluwer Academic Publishers; 1996. p. 82–4.
5. Schlaeppi M, Ruegg C, Tran-Thang C, Chapuis G, Tevaearai H, Lahm H, et al. Role of integrins and evidence for two distinct mechanisms mediating human colorectal carcinoma cell interaction with peritoneal mesothelial cells and extracellular matrix. Cell Adhes Commun. 1997;4:439–55.
https://doi.org/10.3109/15419069709004460
.